Board
Alan Reade - Executive Chairman
Mr Reade was appointed on May 25, 2007. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi- Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global at Rhone-Poulenc Inc. previously has been a director of Sygen International and IFAH, a global animal health association as well as more than 40 Merial subsidiaries.
He is chairman of the Remuneration Committee and member of the Nominations Committee .
Barrington Marshall Riley - Independent Non-executive Director
Mr. Riley was appointed on May 25, 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International Plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007.
He is chairman of the Audit Committee and member of the Nominations Committee.
Ken Noonan - Independent Non-executive Director.
Dr. Noonan was appointed on May 25, 2007. He was a Partner at LEK Consulting LLP based in London, where he led the firm's life sciences practice in the UK and Europe, with responsibility for pharmaceuticals, biotechnology and in vitro diagnostics until he retired in 2008. He is currently a technology partner at Advanced Technology Partners. Other positions held by Dr. Noonan included Senior Vice President of Corporate Development for Applera Corporation and Vice President at Booz-Allen & Hamilton and head of its European Pharmaceutical Practice. He currently serves on the Board of Orchid Biosciences Inc. and Intercept Pharmaceuticals Inc. During his academic career he authored over 50 articles in the cancer biology/cell replication and holds a B.S. from St. Joseph's University and a Ph.D. in Biochemistry from Princeton University.
He is a member of the Audit Committee and of the Remuneration Committee.
Patrick Regan - Non-executive Director.
Mr Regan was appointed on September 15, 2009. He has been employed as a senior managing director for Laurus Capital Management LLC for over 8 years. Mr. Regan also serves the same role for Valens Capital Management, LLC since its establishment in 2007. Prior to joining Laurus in 2001, Mr. Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm for two years. Prior to this, Mr. Regan spent four years as a financial analyst at Geller & Company, afinancial services accounting firm primarily providing CFO functions to private companies and financial planning for high net worth individuals. While at Geller, Mr. Regan completed and received his CPA certification (which he no longer maintains) and was involved in private placement financing, management consulting and general corporate finance functions. Mr. Regan received his B.S. in Business and Economics from Lehigh University in 1994 and his M.B.A. from Fordham University in 2000.
Geoffrey N. Vernon - Non-Executive Director
Dr. Vernon was appointed on May 25, 2007. He is Chairman of XLTech Group, Inc. and is a former executive director of Rothschild Asset Management Ltd., partner of the venture capital group Advent Limited, and has over 20 years' experience in healthcare and life sciences. Dr. Vernon is chairman and/or non-executive director of a number of quoted and privately owned companies in the UK, Germany, Ireland and Israel. He is also a Fellow of the Institute of Directors and one of the first directors in the UK to be admitted as a Chartered Director.
He is member of the Audit Committee and chairman of the Nomination Committee.
Keith Bigsby - Chief Financial Officer
Mr. Bigsby was appointed on April 27, 2007. After qualifying as a Chartered Accountant, Mr. Bigsby has had over 30 years of senior financial management and board room experience in the technology sector. He has held senior finance positions across Europe, the USA and the Far East, a significant proportion of which has been as Chief Financial Officer (including for publicly listed companies) most recently at Geotrupes Energy Plc and Tadpole Technology Plc. Prior to this he was for six years the European Regional CFO for Wang and held Regional Finance Director roles in the UK and France for Sun Microsystems. He has a significant background in complex business environments, strategic planning and process re-engineering.